Related Experiment Video
Updated: Jan 11, 2026

Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
Postoperative antithrombotic therapy after coronary artery bypass grafting combined with coronary endarterectomy
Xieraili Tiemuerniyazi1, Ziang Yang1, Enze Yang2
1Department of Cardiovascular Surgery, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, Beijing, China.
Insights
This randomized trial compares dual antiplatelet therapy versus dual antiplatelet therapy plus warfarin after coronary endarterectomy and bypass grafting. The study aims to find the best antithrombotic strategy to improve coronary graft patency.
Area of Science:
- Cardiovascular Surgery
- Interventional Cardiology
- Pharmacology
Background:
- Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) is linked to poor graft patency.
- Subendothelial tissue exposure during CE+CABG may activate coagulation, suggesting a need for anticoagulation.
- Optimal antithrombotic therapy post-CE+CABG remains undetermined.
Purpose of the Study:
- To determine the optimal antithrombotic therapy following coronary endarterectomy and coronary artery bypass grafting (CE+CABG).
- To compare the efficacy of dual antiplatelet therapy (AT) versus dual AT plus warfarin (ATW) on coronary graft patency.
Main Methods:
- A randomized controlled trial (PATH-CARE) involving 202 patients.
- Patients assigned to AT (aspirin + clopidogrel) or ATW (aspirin + clopidogrel + warfarin for 3 months).
- Primary endpoint: patency of CE-targeted coronary grafts assessed by angiography; secondary endpoints: major adverse events and bleeding.
Main Results:
- N/A - Results pending study completion.
Conclusions:
- N/A - Conclusions pending study completion.
Introduction:
Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) has been associated with poor graft patency, which might be attributed to the activation of coagulation cascade caused by the exposure of the subendothelial tissue to the blood stream, which could necessitate anticoagulation therapy. However, the optimal antithrombotic therapy after CE+CABG remains unclear.
Methods And Analysis:
The PATH-CARE is a double-centre, two-armed, blinded to outcome assessed, randomised controlled trial, aimed to determine the optimal antithrombotic therapy after CE+CABG. A total of 202 patients are expected to be recruited. Patients will be randomly assigned in a 1:1 ratio to the control (dual antiplatelet therapy (AT) group) and the intervention (dual AT+warfarin (ATW) group). Patients in the AT group will receive aspirin plus clopidogrel for 1 year, while patients in the ATW group receive aspirin plus clopidogrel for 1 year with extra warfarin therapy for the first 3 months postoperatively. All patients will receive life-long aspirin treatment after the first year. All of the patients will be required to complete a 6-month follow-up. The primary endpoint is the patency of CE-targeted coronary grafts, assessed through coronary CT angiography or coronary angiography. Secondary outcomes include the occurrence of major adverse cardiovascular and cerebrovascular events and bleeding events.
Ethics Approval And Dissemination:
This study was approved by the Institutional Review Board of Fuwai Hospital (No.: 2022-1849), and Yunnan Fuwai Cardiovascular Hospital (No.: 2023-048-01). Findings of this trial will be disseminated via peer-reviewed research papers and academic conference presentations.
Trial Registration Number:
NCT05782270.
More Related Videos
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Atherosclerosis III: Management